{"entity":{"id":"nct07081633","kind":"trial","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of Durvalumab, Tremelimumab, Lenvatinib in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07081633 by AstraZeneca, with 114 participants enrolled, started 2025-08-05 and due to reach its primary completion in 2026-11-30. Interventions recorded: Durvalumab, Tremelimumab, Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07081633","url":"https://clinicaltrials.gov/study/NCT07081633"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","tremelimumab","lenvatinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07081633","phase":"2","setting":"An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"AstraZeneca","enrolled":114,"outcomes":[]},"route":"/trials/nct07081633/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}